Sunday, 22 May 2022


Japan’s Daiichi Sankyo divests certain cardiovascular products, shifting focus to oncology

19 January 2022 | News

Divesting select products to US-based Cosette Pharmaceuticals

image credit- shutterstock

image credit- shutterstock

Japan-based pharmaceutical firm Daiichi Sankyo has entered into an agreement with Cosette Pharmaceuticals, Inc. whereby Daiichi Sankyo divested and Cosette acquired rights for manufacturing, commercialization, and certain other rights for the following products in the US.:

AZOR® (amlodipine/olmesartan medoxomil); BENICAR® (olmesartan medoxomil); BENICAR HCT® (olmesartan medoxomil/hydrochlorothiazide); EFFIENT® (prasugrel); EVOXAC® (cevimeline HCL); TRIBENZOR® (olmesartan medoxomil/amlodipine/hydrochlorothiazide); WELCHOL® (colesevelam HCL) tablets; and WELCHOL® (colesevelam HCL) Oral Suspension.

“As part of our 2030 vision of becoming a global top 10 leader in oncology, we are shifting our structure to focus on our oncology portfolio in the US, while ensuring these legacy medicines continue to be available to the patients who rely on them,” said Ken Keller, President & CEO, Daiichi Sankyo, Inc.

The agreement outlines a 30-month transition period during which Daiichi Sankyo and Cosette Pharmaceuticals will transfer responsibilities for the manufacture, supply and commercialization of these products, including quality assurance, pharmacovigilance and regulatory matters.

 

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account